Anti-psoriatic therapy recovers high-density lipoprotein composition and function

Journal of Investigative Dermatology

Volumn 134, Issue 3, 2014, Pages 635-642

  Holzer, Michael ^a   Wolf, Peter ^a   Inzinger, Martin ^a   Trieb, Markus ^a   Curcic, Sanja ^a   Pasterk, Lisa ^a   Weger, Wolfgang ^a   Heinemann, Akos ^a   Marsche, Gunther ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIPSORIASIS AGENT; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; LIPOLYSIS; MACROPHAGE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSORIASIS; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTIGENS, HUMAN PLATELET; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; LIPOLYSIS; LIPOPROTEINS, HDL; MACROPHAGES; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PSORIASIS; PUVA THERAPY; RISK FACTORS; TRITIUM;

EID: 84894050766     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.359     Document Type: Article

References (30)

1. Ahlehoff O, Skov L, Gislason G et al. (2013) Cardiovascular disease event rates in patients with severe psoriasis treated with systemic antiinflammatory drugs: a danish real-world cohort study. J Intern Med 273:197-2044
2. Armstrong EJ, Harskamp CT, Armstrong AW(2013) Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2:e0000622
3. Asztalos BF, de la Llera-Moya M, Dallal GE et al. (2005) Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 46:2246-533
4. Aviram M (2011) Atherosclerosis: cell biology and lipoproteins- inflammation and oxidative stress in atherogenesis: protective role for paraoxonases. Curr Opin Lipidol 22:243-44
5. Bhattacharyya T, Nicholls SJ, Topol EJ et al. (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299: 1265-766
6. Calabresi L, Favari E, Moleri E et al. (2009) Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis 204:141-66
7. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF et al. (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30: 796-8011
8. Hine D, Mackness B, Mackness M (2012) Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life 64:157-611
9. Holzer M, Birner-Gruenberger R, Stojakovic T et al. (2011a) Uremia alters HDL composition and function. J Am Soc Nephrol 22:1631-411
10. Holzer M, Gauster M, Pfeifer T et al. (2011b) Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 14: 2337-466
11. Holzer M, Wolf P, Curcic S et al. (2012) Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53:1618-244
12. Kaplan MJ (2008) Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vasc Health Risk Manag 4:1229-355
13. Khera AV, Cuchel M, de la Llera-Moya M et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127-355
14. Kontush A, Chapman MJ (2010) Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 21:312-88
15. Kunnen S, Van Eck M (2012) Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res 53:1783-999
16. Landmesser U, von Eckardstein A, Kastelein J et al. (2012) Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? the early demise of the dal-HEART programme. Eur Heart J 33:1712-55
17. Li XM, TangWH, Mosior MK et al. (2013) Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33:1696-7055
18. Mackness B, Mackness M (2010) Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv Exp Med Biol 660:143-511
19. Marsche G, Saemann MD, Heinemann A et al. (2013) Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol Ther 137:341-511
20. Mehta NN, Azfar RS, Shin DB et al. (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 31:1000-66
21. Mehta NN, Li R, Krishnamoorthy P et al. (2012) Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 224:218-211
22. Neimann AL, Shin DB, Wang X et al. (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829-355
23. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. (2001) Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 303:33-99
24. Rosenson RS, Stafforini DM (2012) Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res 53:1767-822
25. Sankaranarayanan S, Oram JF, Asztalos BF et al. (2009) Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res 50:275-844
26. Shah AS, Tan L, Lu Long J et al. (2013) The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 54:2575-855
27. Toker A, Kadi M, Yildirim AK et al. (2009) Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 27:176-800
28. Triolo M, Annema W, Dullaart RP et al. (2013) Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med 7:457-722
29. Voight BF, Peloso GM, Orho-Melander M et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572-800
30. Yancey PG, de la Llera-Moya M, Swarnakar S et al. (2000) High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 275:36596-6044